WO2025186726 - MODULATING EXPRESSION OF AGT (ANGIOTENSINOGEN) GENE
National phase entry is expected:
Publication Number
WO/2025/186726
Publication Date
11.09.2025
International Application No.
PCT/IB2025/052358
International Filing Date
04.03.2025
Title **
[English]
MODULATING EXPRESSION OF AGT (ANGIOTENSINOGEN) GENE
[French]
MODULATION DE L'EXPRESSION D'UN GÈNE AGT (ANGIOTENSINOGÈNE)
Applicants **
CRISPR THERAPEUTICS AG
Inventors
DEQUEANT, Mary-Lee
KYRYCHENKO, Viktoriia
D'SOUZA, Sanjay
Priority Data
63/561,723
05.03.2024
US
63/643,087
06.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4123 | |
| EPO | Filing, Examination, Granting | 46476 | |
| Japan | Filing, Examination, Granting | 3696 | |
| South Korea | Filing, Examination, Granting | 5063 | |
| USA | Filing, Examination, Granting | 21190 |
Total:
80,548
Contact Us
Abstract[English]
The present disclosure relates to methods, compositions and kits for treating conditions that are related to the modulation of expression of angiotensinogen (AGT) gene by gene editing.[French]
La présente divulgation concerne des méthodes, des compositions et des kits destinés à traiter des états pathologiques qui sont liés à la modulation de l'expression du gène de l'angiotensinogène (AGT) par modification génique.